Electra Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against...
Day: January 5, 2026
Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism
REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel...
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
TARA-002 selected for FDA manufacturing development and readiness pilot programNEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc....
Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials
-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing...
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with...
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on...
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and...
HOOPP hits 500,000-member milestone, strengthening retirement security for Ontario’s healthcare community
Half a million futures. One pension promise.TORONTO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Healthcare of Ontario Pension Plan has...
Compass Therapeutics Announces Key Leadership Appointments
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
Exclusive distribution agreement includes revenue sharing in addition to upfront and milestone payments to LENZSAN DIEGO and DUBAI, United Arab...
BlossomHill Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12
SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design...
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
Clearance would position the Ceribell System as the first and only point-of-care electroencephalography (EEG) technology to aid in detection and...
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel
- Expansion plans are based on requests for product access received from surgeons and hospitals in Israel - - Expansion...
GoGo AI Network Inc. Announces New Trading Symbols (CSE: GOGO and OTCQB: GGGGF) and New Corporate Website
VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) -- GoGo AI Network Inc. (CSE: GOGO) (OTC Markets: GGGGF) (FSE: Y30)...
Prenetics Provides Update on Voluntary Warrant Exchange Program, Reaching 86.7% Participation
CHARLOTTE, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health...
Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference
Media ReleaseCOPENHAGEN, Denmark; January 5, 2026Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company...
Angitia Biopharmaceuticals Completes Enrollment of Phase 2 ARTEMIS Trial Evaluating AGA2118 for the Treatment of Osteoporosis
- Company expects topline data from the study in 2027 WESTLAKE VILLAGE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Angitia...
Validic Powers Scalable AI-Driven Remote Care at CES 2026
AI-powered infrastructure supports CMS ACCESS programs with EHR-integrated insights for health systems and chronic care organizationsLAS VEGAS, Jan. 05, 2026...
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDAGAITHERSBURG, Md.,...
ElevateBio Appoints Christopher Murphy as Chief Executive Officer and Member of the Board of Directors
Christopher Murphy brings more than 35 years of industry experience in commercializing medicines, delivering profitable growth and biomanufacturing excellence Christopher...